Home / Pharmaceuticals / Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs Type (Top 3 Countries, Chemotherapy Drugs, Pipeline Drugs) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Acute Myeloid Leukemia (AML) Therapeutics Market By Drugs Type (Top 3 Countries, Chemotherapy Drugs, Pipeline Drugs) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Published: Sep 2017 | Report Code: 58717-09-17

Acute myeloid leukemia (AML) is type of blood and bone marrow cancer characterized by abnormal production of myeloid blasts in the bone marrow and peripheral blood. Rising incidence of AML, higher number of unmet needs, expected launch of ideal molecules and technological advances are prime factors that driving the growth of AML therapeutics market globally.

The report titled “Acute Myeloid Leukemia (AML) therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall AML therapeutics market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug type (chemotherapy drugs and pipeline drugs) and different geographical regions. Geographically, the global AML therapeutics market is studied for the following regional markets:   

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of MEA

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global AML therapeutics market. Pipeline analysis and global epidemiology data has been included in report. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global AML therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global AML therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global AML therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Acute Myeloid Leukemia (AML) Therapeutics Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Snapshot
2.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
2.3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share, by Geography, 2016 (Value %)

Chapter 3 Acute Myeloid Leukemia (AML) Therapeutics Market Analysis
3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Acute Myeloid Leukemia (AML) Therapeutics
3.4 Global Epidemiology of Acute Myeloid Leukemia (AML)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Acute Myeloid Leukemia (AML) Therapeutics Market

Chapter 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type
4.3 Top 3 Countries
4.4 Chemotherapy Drugs
4.4.1 Cytarabine
4.4.2 Anthracyclines
4.4.3 Etoposide
4.4.4 Other
4.5 Pipeline Drugs

Chapter 5 Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.2.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.3.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.5.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
6.3 Boehringer Ingelheim GmbH
6.4 Bristol Myers Squibb
6.5 Celegene Corporation
6.6 Cephalon Inc.
6.7 Eisai Co. Ltd.
6.8 Eli Lilly and Company
6.9 Genzyme Corporation (A subsidiary of Sanofi S.A.)
6.10 Jazz Pharmaceuticals, Inc.
6.11 Novartis AG
6.12 Pfizer Inc.

List of Tables :

TABLE 1 Market Positioning of Key Players in Global Acute Myeloid Leukemia (AML) Therapeutics Market
TABLE 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015 – 2025 (US$ Mn)
TABLE 3 Top 3 Countries in Global Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 6 North America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Celegene Corporation: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Cephalon Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Genzyme Corporation (A subsidiary of Sanofi S.A.): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Jazz Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

List of Figures :

FIG. 1 Acute Myeloid Leukemia (AML) Therapeutics Market: Research Methodology
FIG. 2 Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2016 (US$ Mn)
FIG. 3 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Acute Myeloid Leukemia (AML) Therapeutics Market, by Drugs Type, 2016
FIG. 6 Global Chemotherapy Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Acute Myeloid Leukemia (AML) Cytarabine Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Acute Myeloid Leukemia (AML) Anthracyclines Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Acute Myeloid Leukemia (AML) Etoposide Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Other Drugs in Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Pipeline Drugs in Acute Myeloid Leukemia (AML) Therapeutics Market, 2015 – 2025 (US$ Mn)

Based on the drug type, the global acute myeloid leukemia (AML) therapeutics market is segmented as follows:

  • Chemotherapy Drugs
    • Cytarabine
    • Anthracyclines
  • Daunorubicin
  • Idarubicin
  • Mitoxantrone
    • Etoposide
    • Other
  • Pipeline Drugs

Acute myeloid leukemia (AML) is a cancer of blood and bone marrow, it is characterized by an overproduction of immature myeloblasts or leukaemic blasts. AML therapeutics market expected to show significant market growth during forecast period primarily due to growing prevalence of leukemia and presence of ideal pipeline molecules. Treatment of AML is typically divided into two phases, induction therapy and post-remission therapy. It is studied that, in the base year 2016, cytarabine was major revenue generating segment due to its effectiveness and hence it is primary component of chemotherapy regimens. It is estimated that newly approved drugs such as gemtuzumab ozogamicin, Vyxeos, midostaurin will show significant market growth during forecast period. It is studied that presence of strong pipeline molecules such as Bosutinib, Vosaroxin, Omacetaxine mepesuccinate, Venetoclax or Quizartinib would assist AML therapeutics market growth during forecast period 2017-2025.

 Acute Myeloid Leukemia (AML) Therapeutics Market

For the purpose of this study, the global acute myeloid leukemia (AML) therapeutics market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Acute Myeloid Leukemia (AML) Therapeutics Market

Acute Myeloid Leukemia (AML) is a type of blood cancer characterized by expansion of myeloid blasts in the bone marrow and peripheral blood. According to GLOBOCAN worldwide prevalence of AML is approximately 1.5% and 1.4% for male and female respectively.  It is observed that currently, North America is dominating AML therapeutics market due to developed healthcare infrastructure, advance technologies, higher number of targeted population, upsurge in funding by government agencies and regulatory approval of newer molecules. Furthermore increase in incidence of AML and upcoming regulatory approval of newer molecules would boost the AML therapeutics market during forecast period. American Cancer Society recorded approximately 21,380 new cases and 10,590 deaths from AML in United States in year 2017. It is estimated that, Asia Pacific will show significant AML therapeutics market growth during forecast period due to developing healthcare infrastructure, increasing incidence of AML and rising treatment awareness.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients